What is the purpose of this trial?
This is a randomized phase II study to evaluate if the combination of T-DM1 with palbociclib improves progression-free survival compared to single agent T-DM1in patients with metastatic HER2 positive breast cancer
University of Arizona Cancer Center
Start Date: 01/22/2019
End Date: 09/01/2019
Last Updated: 01/24/2019
Study HIC#: 2000023405